KYMR compared with ALKS: revenue, margins and what each company keeps, and the suppliers and customers both name

KYMRKymera Therapeutics, Inc.

Mkt capRevenueRevenue

ALKSAlkermes plc.

Mkt capRevenueRevenue

Compare

KYMRKymera Therapeutics, Inc.

ALKSAlkermes plc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

KYMRKymera Therapeutics, Inc.

127.54▲+0.72%· post 126.56

Mkt cap$10.8BRevenue$65MQ2 FY26Revenue$39MFY25

ALKSAlkermes plc.

45.12▼−0.49%· post 45.12

ClosedNov 2 '26

Mkt cap$7.6BRevenue$496MQ2 FY26Revenue$1.5BFY25

Compare

ClosedNov 2 '26

KYMRKymera Therapeutics, Inc.

ALKSAlkermes plc.

127.54▲+0.72%post 126.56

Price

45.12▼−0.49%post 45.12

$10.8B

Mkt cap

$7.6B

Q2 FY26$65M

Revenue

$496MQ2 FY26

FY25$39M

Revenue

$1.5BFY25

KYMR127.54▲+0.72%vsALKS45.12▼−0.49%ClosedNov 2 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

KYMR: latest quarter is a loss; flow not drawable. ALKS: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only KYMR 4

GILDGilead Sciencescustomer

VERXVertex Pharmaceuticalscustomer

SNYSanoficustomer

SNYNFSanoficustomer

Shared 0

No shared counterparties.

Only ALKS 4

BIIBBiogencustomer

VEEVVeeva Systemssupplier

TEVATevacustomer

—Amnealunlisted

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

customer

Price

rebased to 0%

KYMR, solidALKS, dashed